— Know what they know.
Not Investment Advice

CRVS NASDAQ

Corvus Pharmaceuticals, Inc.
1W: -4.2% 1M: -26.7% 3M: -21.1% YTD: +78.7% 1Y: +255.4% 3Y: +451.9% 5Y: +423.2%
$12.61
-0.47 (-3.59%)
 
Weekly Expected Move ±13.8%
$9 $11 $12 $14 $16
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 32 · $1.1B mcap · 63M float · 2.22% daily turnover · Short 27% of daily vol

Balance Sheet Trends

Total Assets
$71M +3.2% ▲
5Y CAGR: -3.6%
Total Liabilities
$10M -72.7% ▼
5Y CAGR: -5.8%
Shareholders Equity
$61M +87.9% ▲
5Y CAGR: -3.2%
Cash & Investments
$57M +9.2% ▲
5Y CAGR: +5.1%
Total Debt
$937K -16.5% ▼
5Y CAGR: -16.5%
Net Debt
-$4M +52.2% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$63M$13M$13M$9M$5M
Short-Term Investments$6M$29M$15M$43M$52M
Cash & ST Investments$69M$42M$27M$52M$57M
Net Receivables$539K$633K$63K$216K$374K
Inventory$0$0$0$0$0
Other Current Assets$128K$102K$220K$548K$318K
Total Current Assets$71M$44M$28M$54M$58M
Property, Plant & Equip.$4M$3M$1M$1M$1M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$34M$22M$16M$13M$11M
Other Non-Current Assets$236K$129K$89K$632K$855K
Total Non-Current Assets$38M$25M$18M$14M$13M
Total Assets$109M$68M$46M$69M$71M
— Liabilities —
Accounts Payable$2M$2M$2M$3M$2M
Short-Term Debt$0$0$0$0$403K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$1M$929K$30M$6M
Total Current Liabilities$10M$11M$7M$35M$9M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$3M$1M$0$937K$534K
Total Liabilities$12M$12M$7M$36M$10M
— Equity —
Common Stock$5K$5K$5K$7K$7K
Retained Earnings-$266M-$308M-$335M-$397M-$412M
Accumulated OCI$2M-$563K-$967K-$1M-$896K
Total Stockholders Equity$97M$56M$39M$33M$61M
Total Liabilities & Equity$109M$68M$46M$69M$71M
— Key Metrics —
Total Debt$4M$3M$1M$1M$937K
Net Debt-$60M-$11M-$11M-$8M-$4M
Total Investments$40M$51M$31M$56M$63M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms